FI3939590T3 - Kasvuhormonin puutoksen tunnistaminen ja hoitaminen - Google Patents
Kasvuhormonin puutoksen tunnistaminen ja hoitaminen Download PDFInfo
- Publication number
- FI3939590T3 FI3939590T3 FIEP21192867.6T FI21192867T FI3939590T3 FI 3939590 T3 FI3939590 T3 FI 3939590T3 FI 21192867 T FI21192867 T FI 21192867T FI 3939590 T3 FI3939590 T3 FI 3939590T3
- Authority
- FI
- Finland
- Prior art keywords
- use according
- child
- growth hormone
- hormone deficiency
- dose
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/575—Hormones
- G01N2333/61—Growth hormones [GH] (Somatotropin)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/575—Hormones
- G01N2333/65—Insulin-like growth factors (Somatomedins), e.g. IGF-1, IGF-2
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562221191P | 2015-09-21 | 2015-09-21 | |
| US201662289221P | 2016-01-30 | 2016-01-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI3939590T3 true FI3939590T3 (fi) | 2023-12-14 |
Family
ID=58276481
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP21192867.6T FI3939590T3 (fi) | 2015-09-21 | 2016-09-21 | Kasvuhormonin puutoksen tunnistaminen ja hoitaminen |
Country Status (23)
| Country | Link |
|---|---|
| US (5) | US9763919B2 (enExample) |
| EP (3) | EP3352752B1 (enExample) |
| JP (5) | JP6816149B2 (enExample) |
| KR (4) | KR20230116961A (enExample) |
| CN (2) | CN108348501A (enExample) |
| AU (5) | AU2016328969B2 (enExample) |
| CA (1) | CA2998523C (enExample) |
| CY (1) | CY1125183T1 (enExample) |
| DK (2) | DK3939590T3 (enExample) |
| ES (2) | ES2967259T3 (enExample) |
| FI (1) | FI3939590T3 (enExample) |
| HR (1) | HRP20220317T1 (enExample) |
| HU (2) | HUE065224T2 (enExample) |
| IL (1) | IL258224B (enExample) |
| LT (1) | LT3352752T (enExample) |
| PL (2) | PL3939590T3 (enExample) |
| PT (2) | PT3939590T (enExample) |
| RS (1) | RS62988B1 (enExample) |
| SG (2) | SG10202010598SA (enExample) |
| SI (1) | SI3352752T1 (enExample) |
| SM (1) | SMT202200167T1 (enExample) |
| UA (1) | UA123865C2 (enExample) |
| WO (1) | WO2017053373A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11234969B2 (en) * | 2016-01-30 | 2022-02-01 | Lumos Pharma, Inc. | Detecting and treating growth hormone deficiency |
| CN108348501A (zh) * | 2015-09-21 | 2018-07-31 | 埃莫奈特药业有限责任公司 | 检测和治疗生长激素缺乏症 |
| US10288629B1 (en) * | 2017-12-19 | 2019-05-14 | Aeterna Zentaris, Inc. | Method of assessing growth hormone deficiency in humans by a macimorelin containing composition |
| EP3840854A4 (en) | 2018-08-20 | 2022-06-29 | Bessor Pharma, LLC | Novel cannabinoids and cannabinoid acids and their derivatives |
| US11644474B2 (en) * | 2020-07-22 | 2023-05-09 | Æterna Zentaris Gmbh | Use of macimorelin in assessing growth hormone deficiency in children |
| GEAP202516774A (en) | 2022-11-03 | 2025-06-25 | Lumos Pharma Inc | Compactable oral formulations of ibutamoren |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0650597A4 (en) * | 1992-06-29 | 1996-12-18 | Univ South Florida | DIAGNOSTIC METHOD FOR EVALUATING THE AETIOLOGY OF MINOR GROWTH. |
| US5756507A (en) | 1995-12-14 | 1998-05-26 | Merck & Co., Inc. | Antagonists of gonadotropin releasing hormone |
| AU758160B2 (en) * | 1997-08-22 | 2003-03-20 | Kaken Pharmaceutical Co., Ltd. | Novel amide derivatives |
| ATE446758T1 (de) | 2000-05-31 | 2009-11-15 | Pfizer Prod Inc | Verwendung von wachstumshormonsekretagoga zur förderung der beweglichkeit des verdauungstrakts |
| ATE302181T1 (de) * | 2000-06-13 | 2005-09-15 | Zentaris Gmbh | Verbindungen zur stimulation der sekretion von wachstumshormonen |
| US20070037861A1 (en) * | 2003-09-19 | 2007-02-15 | Pfizer Health Ab | Enhanced method of treatment of growth disorders |
| AU2004288831B2 (en) * | 2003-11-12 | 2010-08-26 | Phenomix Corporation | Heterocyclic boronic acid compounds |
| GB0603295D0 (en) | 2006-02-18 | 2006-03-29 | Ardana Bioscience Ltd | Methods and kits |
| US20150119327A1 (en) * | 2012-04-25 | 2015-04-30 | The Regents Of The University Of California | Drug screening platform for rett syndrome |
| US11234969B2 (en) * | 2016-01-30 | 2022-02-01 | Lumos Pharma, Inc. | Detecting and treating growth hormone deficiency |
| CN108348501A (zh) * | 2015-09-21 | 2018-07-31 | 埃莫奈特药业有限责任公司 | 检测和治疗生长激素缺乏症 |
-
2016
- 2016-09-21 CN CN201680064316.4A patent/CN108348501A/zh active Pending
- 2016-09-21 US US15/271,542 patent/US9763919B2/en active Active
- 2016-09-21 SG SG10202010598SA patent/SG10202010598SA/en unknown
- 2016-09-21 HU HUE21192867A patent/HUE065224T2/hu unknown
- 2016-09-21 RS RS20220218A patent/RS62988B1/sr unknown
- 2016-09-21 ES ES21192867T patent/ES2967259T3/es active Active
- 2016-09-21 DK DK21192867.6T patent/DK3939590T3/da active
- 2016-09-21 KR KR1020237025351A patent/KR20230116961A/ko not_active Ceased
- 2016-09-21 CN CN202310486498.6A patent/CN116459250A/zh active Pending
- 2016-09-21 CA CA2998523A patent/CA2998523C/en active Active
- 2016-09-21 SI SI201631495T patent/SI3352752T1/sl unknown
- 2016-09-21 PL PL21192867.6T patent/PL3939590T3/pl unknown
- 2016-09-21 HU HUE16849470A patent/HUE057831T2/hu unknown
- 2016-09-21 LT LTEPPCT/US2016/052800T patent/LT3352752T/lt unknown
- 2016-09-21 UA UAA201803953A patent/UA123865C2/uk unknown
- 2016-09-21 EP EP16849470.6A patent/EP3352752B1/en active Active
- 2016-09-21 FI FIEP21192867.6T patent/FI3939590T3/fi active
- 2016-09-21 ES ES16849470T patent/ES2908423T3/es active Active
- 2016-09-21 EP EP23207876.6A patent/EP4296679A3/en active Pending
- 2016-09-21 PT PT211928676T patent/PT3939590T/pt unknown
- 2016-09-21 KR KR1020187010804A patent/KR102385669B1/ko active Active
- 2016-09-21 HR HRP20220317TT patent/HRP20220317T1/hr unknown
- 2016-09-21 AU AU2016328969A patent/AU2016328969B2/en active Active
- 2016-09-21 PT PT168494706T patent/PT3352752T/pt unknown
- 2016-09-21 PL PL16849470T patent/PL3352752T3/pl unknown
- 2016-09-21 KR KR1020227011483A patent/KR102560838B1/ko active Active
- 2016-09-21 JP JP2018534488A patent/JP6816149B2/ja active Active
- 2016-09-21 SG SG10201902424TA patent/SG10201902424TA/en unknown
- 2016-09-21 SM SM20220167T patent/SMT202200167T1/it unknown
- 2016-09-21 EP EP21192867.6A patent/EP3939590B1/en active Active
- 2016-09-21 DK DK16849470.6T patent/DK3352752T3/da active
- 2016-09-21 KR KR1020257020814A patent/KR20250102122A/ko active Pending
- 2016-09-21 WO PCT/US2016/052800 patent/WO2017053373A1/en not_active Ceased
-
2017
- 2017-09-18 US US15/706,991 patent/US10105352B2/en active Active
-
2018
- 2018-03-19 IL IL258224A patent/IL258224B/en unknown
- 2018-09-20 US US16/136,967 patent/US10898472B2/en active Active
-
2020
- 2020-09-17 AU AU2020233715A patent/AU2020233715B2/en active Active
- 2020-12-23 JP JP2020213095A patent/JP7104768B2/ja active Active
-
2021
- 2021-10-21 AU AU2021254600A patent/AU2021254600B2/en active Active
-
2022
- 2022-01-24 US US17/582,117 patent/US12539293B2/en active Active
- 2022-03-18 CY CY20221100219T patent/CY1125183T1/el unknown
- 2022-07-08 JP JP2022110116A patent/JP7389862B2/ja active Active
-
2023
- 2023-11-17 JP JP2023195764A patent/JP7724831B2/ja active Active
-
2024
- 2024-03-14 AU AU2024201658A patent/AU2024201658C1/en active Active
-
2025
- 2025-03-21 US US19/086,686 patent/US20250213536A1/en active Pending
- 2025-08-05 JP JP2025130430A patent/JP2025170274A/ja active Pending
- 2025-09-24 AU AU2025237934A patent/AU2025237934A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Tazi et al. | Treatment of cachexia in oncology | |
| CY1124052T1 (el) | Δισκιο διασπειρομενο στο στομα περιεχον οιστετρολη | |
| Mantovani et al. | Cancer cachexia: medical management | |
| CY1124104T1 (el) | Δισκιο διασπειρομενο στο στομα περιεχον οιστετρολη | |
| EP4233892A3 (en) | Stable anti-ifnar1 formulation | |
| EA200801671A1 (ru) | Специфическая терапия, использующая интегриновые лиганды для лечения рака | |
| MA43283B1 (fr) | Composition pour le traitement du cancer | |
| MX2013005341A (es) | Formulaciones liquidas de anticuerpos anti-tnf-alfa de alta concentracion mejoradas. | |
| EA201270167A1 (ru) | Лекарственная форма глатирамера ацетата с уменьшенным объемом и способы введения | |
| CL2021003474A1 (es) | Producto farmacéutico para terapia enzimática para tratamiento de homocistinuria | |
| SI2922576T1 (en) | Methods of administering and evaluating nitrogen scavenging drugs for the treatment of hepatic encephalopathy | |
| HRP20220317T1 (hr) | Otkrivanje i liječenje nedostatka hormona rasta | |
| TW201417806A (zh) | 用於改善兒童的線性生長反應之方法 | |
| BR112012030641A2 (pt) | métodos e composições para terapia farmacêutica oral | |
| JP2019530706A5 (enExample) | ||
| PL2131810T3 (pl) | Podawanie doustne kalcytoniny | |
| JP2018529766A5 (enExample) | ||
| McDonough | Naltrexone and liver disease | |
| MX2015010594A (es) | Esteres de testosterona de cadena larga lipobalanceados para suministro oral. | |
| Liu et al. | Blockade of hypoxia-inducible factor-1α by YC-1 attenuates interferon-γ and tumor necrosis factor-α-induced intestinal epithelial barrier dysfunction | |
| JP2019504860A5 (enExample) | ||
| Yu et al. | TNF reduces LIF endocytosis despite increasing NFκB‐mediated gp130 expression | |
| ATE395936T1 (de) | Dichloracetat in kombination mit kardioprotektiven oder hämodynamischen medikamenten | |
| PH12018500889A1 (en) | Pharmaceutical preparation for delivery of porous material to large intestine or lower part of small intestine | |
| NZ741142B2 (en) | Detecting and treating growth hormone deficiency |